POTASSIUM CHLORIDE

This product is only for use in clinical care situations. 4mmol/ml Solution for infusion is a ready to use infusion bag. Dosage depends on the serum ionogram value and the acid-base state. 5 – actual serum potassium (MMOL)). 2). It is recommended not to exceed 2-3 MMOL potassium per kg body weight in 24 hours.

Adults (including the elderly):

Up to 6g (80 mmol) daily Paediatric population: Up to 3mmol per kg per day. Children over 25 kg refer to the adult dose. Infusions should be administered slowly over at least 2-3 hours. Method of Administration Slow intravenous infusion, infuse at a rate not exceeding 20 mmol potassium per hour using an infusion pump.

To be used only via a central venous route. In the treatment of severe hypokalaemia or diabetic ketoacidosis, the higher concentration and a higher infusion rate may be required. In this case the infusion should be into a high blood flow vein and continuous ECG monitoring is advisable.

The following convention has been used for the classification of undesirable effects in terms of frequency: very common (≥1/10), common (≥1/100 to < 1/10), uncommon (≥1/1,000 to < 1/100), rare (≥1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data) System Organ Class Frequency Adverse events Metabolism and nutrition disorders Not known Hyperkalaemia1 Nervous system disorders Not known Paraesthesia1, paralysis1 Cardiac disorders Not known Cardiac arrhythmias1, cardiac arrest1 Vascular disorders Not known Phlebitis2, hypotension1 Musculoskeletal and connective tissue disorders Not known Muscle weakness1 General disorders and administration site conditions Not known Pain2 Gastrointestinal disorders Not known Nausea and vomiting3, oesophageal or small bowel ulceration 1Excessive intake of potassium.

2Pain at the injection site and phlebitis may occur during IV administration of solutions containing 30 mmol potassium or more per litre. 3Severe symptoms may indicate obstruction. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

This product must be given by slow intravenous infusion, under ECG control, ensuring adequate urine flow and with careful monitoring of electrolytes. Plasma potassium concentration must be measured at regular intervals to avoid the development of hyperkalaemia, especially in patients with renal impairment.

Potassium salts should be administered with considerable care to patients with renal and adrenal insufficiency, intestinal stricture, history of peptic ulcer, cardiac disease, acute dehydration, heat cramps, extensive tissue destruction as occurs with severe burns, or to patients receiving potassium sparing diuretics or other medications which may increase plasma potassium levels.

Initial potassium replacement therapy should not involve glucose infusions, because glucose may cause a further decrease in the plasma potassium concentration.

1. • Sterile Potassium Chloride Concentrate should never be used undiluted. • Hyperkalaemia (plasma-potassium concentration above 5 mmol/litre) • Impaired renal function with oliguria, anuria or azotaemia • Hyperchloraemia • Addison's disease • Acute dehydration • Heat cramps